Aduhelm (aducanumab)

Aduhelm is not recommended for approval/coverage by EviCore due to insufficient evidence of clinical benefit and demonstrated safety concerns, with no data supporting use outside the trial‑studied population. If considered, requests must document an FDA‑approved Alzheimer's diagnosis, that the patient is in the mild cognitive impairment or mild dementia stage, and that applicable safety criteria and specific coverage guidelines are met.

"FDA-approved indication: treatment of Alzheimer's disease."

Sign up to see full coverage criteria, indications, and limitations.